Several non-covalent CTSC inhibitors, such as compounds CX54, B22, and MOD06051, have been reported for the treatment of lung injury, IBD, and neutrophil associated inflammatory diseases [19,20,21,22]. Here, CTSC is linked to inflammatory bowel disease.